Publication:
Inhibition of RANK signaling as a potential immunotherapy in breast cancer.

Simple item page
dc.contributor.authorGómez-Aleza, C
dc.contributor.authorGonzález-Suárez, E
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC)
dc.date.accessioned2024-10-16T12:06:33Z
dc.date.available2024-10-16T12:06:33Z
dc.date.issued2021-05-14
dc.description.abstractRANK signaling in mouse mammary tumor cells exerts an immunosuppressive environment by promoting the infiltration of pro-tumorigenic neutrophils and preventing CD8 T cell recruitment. Single-agent denosumab led to an increased tumor immune infiltration by lymphocytes and CD8 + T cells in breast cancer patients, supporting the immunomodulatory role of RANK signaling.
dc.description.peerreviewedSí
dc.format.number1
dc.format.page1923156
dc.format.volume10
dc.identifier.citationOncoimmunology . 2021 May 14;10(1):1923156.
dc.identifier.journalOncoimmunology
dc.identifier.pubmedID34026334
dc.identifier.urihttps://hdl.handle.net/20.500.12105/25173
dc.language.isoeng
dc.publisherTaylor & Francis INC
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/682935/EU
dc.relation.publisherversionhttp:// 10.1080/2162402X.2021.1923156
dc.repisalud.institucionCNIO
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectRANK
dc.subjectRANKL
dc.subjectbreast cancer
dc.subjectdenosumab
dc.subjectimmunotherapy
dc.titleInhibition of RANK signaling as a potential immunotherapy in breast cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isFunderOfPublicationcb2ee04a-8d42-4a64-b3f6-3c156f222b35
relation.isFunderOfPublication.latestForDiscoverycb2ee04a-8d42-4a64-b3f6-3c156f222b35

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
InhibitionofRANKsignaling_2021.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
Download

Collections

Grupos de investigación